Published in Curr Opin Gastroenterol on May 01, 2004
Profiling of human serum glycans associated with liver cancer and cirrhosis by IMS-MS. J Proteome Res (2008) 1.66
Detection of hepatocellular carcinoma using glycomic analysis. Clin Cancer Res (2009) 1.52
Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res (2008) 1.13
Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum. Carcinogenesis (2007) 0.96
The application of a three-step serum proteome analysis for the discovery and identification of novel biomarkers of hepatocellular carcinoma. Int J Proteomics (2012) 0.84
Glycoprotein disease markers and single protein-omics. Mol Cell Proteomics (2013) 0.83
Hepatocellular carcinoma--rising incidence, changing therapeutic strategies. Wien Med Wochenschr (2006) 0.82
Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review). Oncol Lett (2014) 0.81
Identification of Differential Protein Expression in Hepatocellular Carcinoma Induced Wistar Albino Rats by 2D Electrophoresis and MALDI-TOF-MS Analysis. Indian J Clin Biochem (2015) 0.75
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57
Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One (2011) 2.48
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol (2005) 2.26
MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology (2008) 2.19
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology (2011) 1.98
Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl (2007) 1.96
Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (2011) 1.94
Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. Hepatology (2010) 1.80
Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark (2007) 1.65
Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl (2007) 1.61
Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res (2005) 1.55
SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology (2005) 1.55
Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl (2009) 1.49
Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) (2012) 1.49
Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma. J Clin Gastroenterol (2011) 1.46
Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study. Hepatology (2012) 1.44
Improved post-transplant survival in the United States for patients with cholangiocarcinoma after 2000. Dig Dis Sci (2013) 1.43
Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol (2013) 1.39
Two-color, rolling-circle amplification on antibody microarrays for sensitive, multiplexed serum-protein measurements. Genome Biol (2004) 1.39
Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl (2010) 1.38
Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol (2007) 1.33
An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl (2009) 1.31
Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle technique. AJR Am J Roentgenol (2006) 1.17
Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol (2013) 1.11
Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol (2010) 1.09
Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep (2008) 1.05
Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol (2013) 0.97
Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver. J Magn Reson Imaging (2010) 0.96
Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. Dig Dis Sci (2010) 0.94
Current approaches to the treatment of early hepatocellular carcinoma. Oncologist (2010) 0.93
Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol (2004) 0.92
Staging systems for hepatocellular carcinoma: should we all use the BCLC system? J Hepatol (2006) 0.92
Screening process failures for hepatocellular carcinoma. J Natl Compr Canc Netw (2014) 0.90
Viral hepatitis and hepatocellular carcinoma. Arch Med Res (2007) 0.90
Who decides? Living donor liver transplantation for advanced hepatocellular carcinoma. Transplantation (2006) 0.86
Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? Gastroenterology (2004) 0.85
A multidisciplinary approach to the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2010) 0.84
Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. J Natl Compr Canc Netw (2013) 0.82
Role of liver transplantation in the treatment of cholangiocarcinoma. Expert Rev Anticancer Ther (2009) 0.80
Elevated serum IL-8 is associated with the presence of hepatocellular carcinoma and independently predicts survival. Cancer Invest (2012) 0.79
Can dietary fish intake prevent liver cancer? Gastroenterology (2012) 0.78
Alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 0.78
Immune thrombocytopenic purpura following liver transplantation: a case series and review of the literature. Liver Transpl (2006) 0.77
Interferon therapy and prevention of hepatocellular carcinoma in hepatitis C. Dig Dis Sci (2012) 0.77
Donor factors similarly impact survival outcome after liver transplantation in hepatocellular carcinoma and non-hepatocellular carcinoma patients. Dig Dis Sci (2014) 0.76
Liver transplantation for hepatocellular carcinoma: who benefits and who is harmed? Gastroenterology (2008) 0.76
Prevention of recurrent variceal bleeding: as easy as A.P.C.? Gastrointest Endosc (2002) 0.75
Reply to Giannini and Trevisani. Am J Gastroenterol (2013) 0.75
Modern diagnosis of hepatocellular carcinoma: Utilization of liver biopsy and genomic markers. J Hepatol (2009) 0.75
Hepatocellular carcinoma. Curr Opin Gastroenterol (2002) 0.75
Outcomes of Simultaneous Liver Kidney Transplantation in Patients With Hepatocellular Carcinoma. Transplantation (2017) 0.75
Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. Clin Adv Hematol Oncol (2013) 0.75